Discovery and mechanism of action of pegvisomant

European Journal of Endocrinology, Supplement

Volumn 148, Issue 2, 2003, Pages

  Kopchick, John J ^a  

^a OHIO UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCINE; GROWTH HORMONE; HORMONE ANTAGONIST; PEGVISOMANT;

AMINO ACID SUBSTITUTION; ANIMAL MODEL; ANTIBODY PRODUCTION; BINDING SITE; CONFERENCE PAPER; EXTRACELLULAR MATRIX; GENE DISRUPTION; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; NONHUMAN; PHENOTYPE; STRUCTURE ACTIVITY RELATION; TRANSGENIC MOUSE; X RAY CRYSTALLOGRAPHY;

ANIMALS; HUMAN GROWTH HORMONE; HUMANS; MODELS, MOLECULAR; RECEPTORS, SOMATOTROPIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037847547     PISSN: 08044635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Okada S & Kopchick JJ. Biological effects of growth hormone and its antagonist. Trends in Molecular Medicine 2001 7 126-132.
2. Kopchick JJ & Andry JM. Growth hormone (GH). GH receptor, and signal transduction. Molecular Genetics and Metabolism 2000 71 293-314.
3. Wells JA, Cunningham BC, Fuh G, Lowman HB, Bass SH, Mulkerrin MG et al. The molecular basis for growth hormonereceptor interactions. Recent Progress in Hormone Research 1993 48 253-275.
4. Abdel-Meguid SS, Shieh HS, Smith WW, Dayringer HE, Violand BN & Bentle LA. Three-dimensional structure of a genetically engineered variant of porcine growth hormone. PNAS 1993 84 6434-6437.
5. Leung DW, Spencer SA, Cachianes G, Hammonds RG, Collins C, Henzel WJ et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987 330 537-543.
6. Ultsch M, De Vos AM & Kossiakoff AA. Crystals of the complex between human growth hormone and the extracellular domain of its receptor. Journal of Molecular Biology 1991 222 865-868.
7. Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR & Wells JA. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 1991 254 821-825.
8. De Vos AM, Ultsch M & Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992 255 306-312.
9. Tou JS, Kaempfe LA, Vineyard BD, Buonomo FC, Della-Fera MA & Baile CA. Amphiphilic growth hormone releasing factor (GRF) analogs: peptide design and biological activity in vivo. Biochemical and Biophysical Research Communications 1986 139 763-770.
10. Chen WY, Wight DC, Wagner TE & Kopchick JJ. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. PNAS 1990 87 5061-5065.
11. Chen WY, White ME, Wagner TE & Kopchick JJ. Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice. Endocrinology 1991 129 1402-1408.
12. Harding PA, Wang X, Okada S, Chen WY, Wan W & Kopchick JJ. Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization. Journal of Biological Chemistry 1996 271 6708-6712.
13. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. Journal of Clinical Endocrinology and Metabolism 2001 86 1716-1723.
14. Chen WY, Wight DC, Mehta BV, Wagner TE & Kopchick JJ. Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Molecular Endocrinology 1991 5 1845-1852.
15. Chen WY, Chen N, Yun J, Wagner TE & Kopchick JJ. In vitro and in vivo studies of the antagonistic effects of human growth hormone analogs. Journal of Biological Chemistry 1994 269 15892-15897.
16. Chen WY, Chen NY, Yun J, Wagner TE & Kopchick JJ. In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. Journal of Biological Chemistry 1994 269 15892-15897.
17. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV & Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science 1992 256 1677-1680.
18. Clark R, Olson K, Fuh G, Marian M, Mortensen D, Teshima G et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. Journal of Biological Chemistry 1996 271 21969-21977.
19. Drake WM, Parkinson C, Besser GM & Trainer PJ. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends in Endocrinology and Metabolism 2001 12 408-413.
20. Cunningham BC & Wells JA. Rational design of receptor-specific variants of human growth hormone. PNAS 1991 88 3407-3411.
21. Goffin V, Bernichtein S, Carriere O, Bennett WF, Kopchick JJ & Kelly PA. The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology 1999 140 3853-3856.
22. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ et al. Treatment of agromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177.
23. Van Der Lely AJ, Hutson R, Trainer PJ, Besser GM, Barkan A, Katznelson L et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
24. Kopchick JJ, Stevens E, Parker C & Trainer P. Growth hormone receptor antagonists. Endocrine Reviews 2002 23 623-646.